DIA 48th Annual Meeting
Click here to go to the previous page
Strategies for Implementing Dried Blood Spot Drug Development and How the Technology Supports the 3Rs Principles
Track
:
Track 04: Nonclinical and Translational Development/Early Phase Clinical Development
Program Code:
417
Date:
Thursday, June 28, 2012
Time:
10:45 AM to 12:15 PM
EST
CHAIR
:
Fumin Li, Covance, Inc., United States
PRESENTER
(S):
Patricia Zane, Sanofi, United States John Dunn, GlaxoSmithKline, United States Enaksha Wickremsinhe, Eli Lilly and Company, United States
Description
Dried blood spot (DBS) sampling is gaining momentum as an alternative to plasma in support of drug discovery and development. DBS provides significant ethical benefits with reduced animal usage, using the 3Rs principle (animal reduction, refinement, and replacement), and higher data quality in safety assessment.
Learning Objectives:
Discuss the backgrounds of dried blood spot (DBS) and the 3Rs principle (animal reduction, refinement and replacement)
Describe DBS nonclinical and clinical benefits
Evaluate the DBS impact on drug discovery and development.
Learning Objectives:
Discuss the backgrounds of dried blood spot (DBS) and the 3Rs principle (animal reduction, refinement and replacement)
Describe DBS nonclinical and clinical benefits
Evaluate the DBS impact on drug discovery and development.
This session is a part of:
Handout Online
